Skip to main content
Full access
Letters
Published Online: 1 January 2014

Long-Term Duloxetine Withdrawal Syndrome and Management in a Depressed Patient

This article has been corrected.
VIEW CORRECTION
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Serotonin and norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine,1 have been reported to be associated with withdrawal syndromes. However, duloxetine-related withdrawal syndrome is infrequently mentioned. We want to report on a depressed patient who experienced a long-term duloxetine withdrawal syndrome and relief after gradual tapering procedures.

Case Report

“Miss B” was a depressed patient (depressed mood, anhedonia, anergia, binge eating, and suicide ideation) with partial remission of symptoms under duloxetine treatment (60 mg/day) for 1 year. However, she disliked the side effects of duloxetine (dizziness and sedation). Therefore, duloxetine was abruptly switched to bupropion 150 mg/day. She started to feel more energy, but with intermittent severe nausea, unexplained fear, and dizziness after quitting duloxetine for 1 day. She still had withdrawal symptoms once-to-twice every week in the following 6 months after the switch. She took duloxetine 30 mg only while feeling withdrawal discomfort in the next 3 months, and then took 15 mg (discarding half the dose of the 30-mg capsule) in the same way for the last month. She took 10 months to recover from long-term and intermittent duloxetine withdrawal syndrome. No residual withdrawal syndrome was noted since that time.

Discussion

Venlafaxine has a higher selectivity of serotonin receptor (30-fold versus norepinephrine) than duloxetine (10-fold).2 Perahia et al. reported that discontinuation-emergent adverse effects of duloxetine happened in around 44.3% of patients, versus 22.9% in a placebo group. They found that duloxetine withdrawal syndrome included dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmares,3 which were similar to the symptoms of this patient. Duloxetine withdrawal syndrome is similar to that seen in discontinuation of SNRIs and serotoninergic-related antidepressants.3 A 10-fold selectivity for serotonin receptor of duloxetine might explain duloxetine withdrawal syndrome in this patient and why it is not so frequent as with venlafaxine, which has 30-fold higher affinity.2 In a current literature search, duloxetine withdrawal syndrome is just mentioned in a few reports.3,4 Besides, a relatively longer half-life of duloxetine (12 hours)5 than the short half-life (5 hours) of venlafaxine,6 and possible genotype polymorphism of Asian people,6 might explain why the long-term and intermittent duloxetine withdrawal syndrome happened in this patient. A gradual tapering-down of duloxetine dose (not an abrupt switch) or occasional re-use of duloxetine while withdrawing might be helpful for this kind of long-term duloxetine withdrawal syndrome.

References

1.
Agelink MW, Zitzelsberger A, Klieser E: Withdrawal syndrome after discontinuation of venlafaxine. Am J Psychiatry 1997; 154:1473–1474
2.
Montgomery SA: Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008; 13(Suppl 11):27–33
3.
Perahia DG, Kajdasz DK, Desaiah D, et al.: Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89:207–212
4.
Abdy NA, Gerhart K: Duloxetine withdrawal syndrome in a newborn. Clin Pediatr (Phila) 2012; 52:976–977
5.
Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23:523–541
6.
Baboolal NS: Venlafaxine withdrawal syndrome: report of seven cases in Trinidad. J Clin Psychopharmacol 2004; 24:229–231

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E04
PubMed: 24515685

History

Published online: 1 January 2014
Published in print: Winter 2014

Authors

Affiliations

Yi-Cheng Hou, MSc
Department of Nutrition, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, ROC
Chien-Han Lai, M.D.
Department of Nutrition, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, ROC

Notes

Corresponding author: Chien-Han Lai, M.D. Department of Psychiatry, Cheng Hsin General Hospital, Taipei City, Taiwan, ROCe-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share